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Abstract
Background: Cutaneous nevi are suggested to be hormone-related. We hypothesized that the number of cutaneous nevi
might be a phenotypic marker of plasma hormone levels and predict subsequent breast cancer risk.
Methods and Findings: We followed 74,523 female nurses for 24 y (1986–2010) in the Nurses’ Health Study and estimate
the relative risk of breast cancer according to the number of cutaneous nevi. We adjusted for the known breast cancer risk
factors in the models. During follow-up, a total of 5,483 invasive breast cancer cases were diagnosed. Compared to women
with no nevi, women with more cutaneous nevi had higher risks of breast cancer (multivariable-adjusted hazard ratio, 1.04,
95% confidence interval [CI], 0.98–1.10 for 1–5 nevi; 1.15, 95% CI, 1.00–1.31 for 6–14 nevi, and 1.35, 95% CI, 1.04–1.74 for 15
or more nevi; p for continuous trend=0.003). Over 24 y of follow-up, the absolute risk of developing breast cancer
increased from 8.48% for women without cutaneous nevi to 8.82% (95% CI, 8.31%–9.33%) for women with 1–5 nevi, 9.75%
(95% CI, 8.48%–11.11%) for women with 6–14 nevi, and 11.4% (95% CI, 8.82%–14.76%) for women with 15 or more nevi. The
number of cutaneous nevi was associated with increased risk of breast cancer only among estrogen receptor (ER)–positive
tumors (multivariable-adjusted hazard ratio per five nevi, 1.09, 95% CI, 1.02–1.16 for ER+/progesterone receptor [PR]–
positive tumors; 1.08, 95% CI, 0.94–1.24 for ER+/PR2 tumors; and 0.99, 95% CI, 0.86–1.15 for ER2/PR2 tumors). Additionally,
we tested plasma hormone levels according to the number of cutaneous nevi among a subgroup of postmenopausal
women without postmenopausal hormone use (n=611). Postmenopausal women with six or more nevi had a 45.5% higher
level of free estradiol and a 47.4% higher level of free testosterone compared to those with no nevi (p for trend=0.001 for
both). Among a subgroup of 362 breast cancer cases and 611 matched controls with plasma hormone measurements, the
multivariable-adjusted odds ratio for every five nevi attenuated from 1.25 (95% CI, 0.89–1.74) to 1.16 (95% CI, 0.83–1.64)
after adjusting for plasma hormone levels. Key limitations in this study are that cutaneous nevi were self-counted in our
cohort and that the study was conducted in white individuals, and thus the findings do not necessarily apply to other
populations.
Conclusions: Our results suggest that the number of cutaneous nevi may reflect plasma hormone levels and predict breast
cancer risk independently of previously known factors.
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Epidemiologic studies have identified a number of hormone-
related risk factors for breast cancer, such as age at menarche, age
at first birth, and age at menopause [1,2]. Further, increased
circulating levels of estradiol and testosterone in postmenopausal
women are consistently associated with increased breast cancer
risk [3–5]. It has been noticed that melanocytic nevi commonly
darken and/or enlarge during pregnancy, suggesting a possible
linkage between nevi and hormones [6,7]. Therefore, we
hypothesized that the number of cutaneous nevi might be a
phenotypic marker of plasma hormone levels, and thus may also
predict the risk of subsequent breast cancer. We conducted a
prospective analysis in the Nurses’ Health Study (NHS), a large
cohort study (121,700 female nurses) with information on self-
counted number of cutaneous nevi. We followed the participants
from 1986, when information on the number of cutaneous nevi
was collected, up to 2010.
Methods
Ethics Statement
The protocol for this study was approved by the Institutional
Review Board at Brigham and Women’s Hospital and the
Harvard School of Public Health. All of the participants provided
informed consent.
Study Population
The NHS cohort was established in 1976, when 121,700 female
registered nurses aged 30 to 55 y completed a baseline question-
naire including items on risk factors for cancer and cardiovascular
disease. Updated risk factor information and disease development
were obtained by follow-up questionnaires every 2 y. Follow-up
has been extremely high, with only 4.4% of person-time lost to
follow-up. Details of this cohort have been described previously
[8].
The baseline was 1986 for this study, when participants
reported self-counted number of cutaneous nevi. From the
baseline cohort of 101,516 women in the 1986 follow-up cycle,
after excluding those who developed cancer before 1986
(n=7,157), those who did not report the number of cutaneous
nevi (n=18,020), and those who were non-white (n=1,816),
74,523 women were included in the analysis.
Exposure Data
In the baseline questionnaire in 1986, the NHS cohort
participants reported numbers of cutaneous nevi on their left
arms from shoulder to wrist of $3 mm diameter size using the
categories of none, 1–2, 3–5, 6–9, 10–14, 15–20, and more than
20. Information on body weight, physical activity, multivitamin
use, smoking status, menopausal status, age at menopause,
postmenopausal hormone (PMH) use, personal history of benign
breast disease (confirmed by breast biopsy), and age at first birth
and parity was collected in the baseline questionnaire and was
updated in the follow-up biennial questionnaires. Information on
alcohol consumption was collected in the follow-up questionnaires
every 4 y beginning in 1986. Information on family history of
breast cancer was collected in the follow-up questionnaires every
4 y beginning in 1988. Information on age at menarche, height,
and body weight at age 18 was collected in 1976. Body mass index
was calculated from body weight and height. Information on hair
color (categorized into red, blond, light brown, dark brown, and
black) and tanning ability (categorized into particularly none, light
tan, average tan, and deep tan) was collected in 1982. Information
on outdoor sun exposure was collected in the 2006 questionnaire.
We asked how many hours per week each participant spent
outdoor in direct sunlight in the middle of the day during summer
during high school and at ages 25–35, 36–59, and 60–65 y. UV
flux for each study participant was estimated based on residential
history according to detailed methods documented previously [9].
Briefly, the potential cumulative UV flux that a participant could
have received over a period of time was estimated by summing the
annual UV flux data over the follow-up period.
Identification of Breast Cancer Cases
Participants reported new breast cancer diagnoses biennially.
For women who did not respond to the questionnaires, we search
the National Death Index routinely for deaths, and the last search
was conducted in December 2010. We asked all women who
reported breast cancer (or next of kin for those who died) for
permission to review the pertinent medical records for confirma-
tion. Information on date of diagnosis was collected from the
medical records as well. Pathology reports, obtained in 96% of the
cases, showed a 99.4% confirmation rate [8]. Eligible cases
consisted of women with incident breast cancer diagnosed any
time between baseline and June 2010, with no previously
diagnosed cancer. Only pathologically confirmed invasive cases
were included in the primary analysis. We included carcinomas in
situ in a secondary analysis. The estrogen receptor (ER) and
progesterone receptor (PR) status of tumors was abstracted from
pathology reports.
Plasma Hormone Study
A subgroup of NHS participants provided plasma samples
between 1989 and 1990. The plasma hormone analysis used 611
controls from a nested case-control study of breast cancer in the
NHS [10]. The controls in this study were women who, at blood
collection, were postmenopausal and had not used PMHs for at
least 3 mo. Hormone assay methods have been described
previously [11,12]. We measured the levels of estradiol, testoster-
one, sex hormone–binding globulin, and dehydroepiandrosterone
sulfate. Free estradiol and free testosterone were calculated by the
law of mass action [13]. Within-batch laboratory coefficients of
variation ranged from 8% to 12%. Details of sample collection and
measurement have been described previously [10]. In addition, we
conducted a case-control study among the 362 breast cancer cases
and 611 matched controls in this subgroup to adjust for plasma
hormone levels in the association between nevus count and breast
cancer.
Statistical Analysis
Participants contributed person-time from the baseline in June
1986 to the end of follow-up. Accumulation of follow-up time
ceased at the diagnosis of any type of cancer, death, or the end of
follow-up, whichever came earliest. We used age- and multivar-
iable-adjusted Cox proportional hazards models to calculate the
hazard ratios (HRs) and 95% confidence intervals (CIs) of breast
cancer according to the number of cutaneous nevi. Based on the
categorical information from the questionnaire, we grouped
women into four categories by number of cutaneous nevi: none,
1–5, 6–14, and 15 or more nevi, and compared each of the last
three groups with the group reporting no nevi. To test for a linear
trend, we modeled the number of cutaneous nevi as a continuous
variable by using the median value of each category and the lower
bound of the top category. In multivariable regression models, we
adjusted for age and additional covariates representing possible
confounders and known breast cancer risk factors, including
Cutaneous Nevi and Breast Cancer Risk
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body mass index, body mass index at age 18 y, height, physical
activity, multivitamin use, family history of breast cancer in a first-
degree relative, cigarette smoking, alcohol consumption, and self-
report of benign breast disease. All variables except age at
menarche and body mass index at age 18 y were updated
throughout follow-up. For postmenopausal women, terms were
also included for duration of menopause and PMH use. To assess
the proportionality assumption, we created interactive terms for
the main predictors and time to event (nevi6time) in the larger
model, and compared the smaller model without any time-
dependent main predictors to the larger model that included all of
the time-dependent main predictors. The test was carried out by a
Wald statistic with one degree of freedom and chi-square
distribution under the null hypothesis. The population attributable
risk (PAR) was calculated basedonthe formula PAR=Pe (HRe21)/
(1+Pe [HRe21]), where Pe is the prevalence of the exposure,
and HRe is the HR of disease due to the exposure. Tests for
interaction were performed using the Wald test for the cross-
product interaction term. In analysis of plasma hormones, because
of the smaller sample size, we collapsed the top nevus count
categories to one: those with six or more nevi. We used generalized
linear models to compare mean hormone levels across subgroups
with different numbers of cutaneous nevi (none, 1–2, 3–5, 6+ nevi
on arm). We controlled for fasting status (,8h ,$8 h), time of day
(24-h clock: ,8, 8–12, 13–24), age at blood draw (continuous),
season of blood draw (May to October, other months), alcohol
intake (continuous), smoking status (never, ever), and body mass
index at blood draw (continuous). For the trend test, we coded the
number of cutaneous nevi as a continuous variable as described
above. All of the statistical analyses were carried out using Statistical
Analysis System software (version 9.1.3; SAS Institute). All p-values
were two-sided.
Results
Among 74,523 women followed from 1986 until 2010, with 1.5
million person-years, 5,483 cases of invasive breast cancer were
documented. In Table 1, we present the basic characteristics of the
study population according to the number of cutaneous nevi.
Women with more cutaneous nevi were more likely to have
hypertension and history of benign breast disease. Among
postmenopausal women, those with more cutaneous nevi were
more likely to be current PMH users. Current smokers, heavier
alcohol consumers, and nulliparous women tended to have fewer
cutaneous nevi. Other breast cancer risk factors were distributed
fairly evenly across the groups of different numbers of cutaneous
nevi. The baseline characteristics were similar between those with
and without information on cutaneous nevi (Table S1).
Women with more cutaneous nevi had a significantly increased
risk of developing subsequent breast cancer (Table 2). After
adjusting for previously known breast cancer risk factors, the HR
was 1.04 (95% CI, 0.98–1.10) for women with 1–5 nevi, 1.15 (95%
CI, 1.00–1.31) for women with 6–14 nevi, and 1.35 (95% CI,
1.04–1.74) for women with 15 or more nevi, compared to those
without cutaneous nevi. Over 24 y of follow-up, the absolute risk
of developing breast cancer increased from 8.48% for women
without cutaneous nevi to 8.82% (95% CI, 8.31%–9.33%) for
women with 1–5 nevi, 9.75% (95% CI, 8.48%–11.11%) for
women with 6–14 nevi, and 11.4% (95% CI, 8.82%–14.76%) for
women with 15 or more nevi. The trend of this increased risk was
significant (p=0.003), and every five additional nevi were
associated with an 8% increase in breast cancer risk (multivari-
able-adjusted HR, 1.08, 95% CI, 1.03–1.13). These results were
not substantially changed by the additional inclusion of 1,084 in
situ breast cancer cases. The distribution of nevus count in our
study population was positively skewed (n=47,052 for none,
18,032 for 1–2 nevi, 5,985 for 3–5 nevi, 1,969 for 6–9 nevi, 820 for
10–14 nevi, 330 for 15–20 nevi, and 325 for more than 20 nevi).
Thus, we considered that the risk estimates for the categorical
groups were more appropriate than those for the continuous count
of nevi. We examined the proportional hazard assumption of
nevus count, and it was valid by statistical tests (p=0.55).
We hypothesized that the number of cutaneous nevi could be a
biomarker of plasma hormone levels, so we further evaluated this
association by ER/PR status of the tumors. Consistent with this
hypothesis, we observed that the number of nevi seemed to be
associated only with the risk of ER-positive cancers (multivariable-
adjusted HR, 1.09, 95% CI, 1.02–1.16 for ER+/PR+ tumors;
1.08, 95% CI, 0.94–1.24 for ER+/PR2 tumors; and 0.99, 95%
CI, 0.86–1.15 for ER2/PR2 tumors, for every five additional
nevi; Table 2). The heterogeneity p-value for this difference was
0.24.
Furthermore, we tested the association between the number of
cutaneous nevi and plasma hormone levels among a subgroup of
611 postmenopausal participants with plasma hormone measure-
ments and without PMH use. We found that women with more
nevi had higher levels of estradiol and testosterone (p for
trend=0.02 for estradiol and 0.06 for testosterone; Table 3).
The associations with free estradiol and free testosterone were
highly significant (45.5% higher level of free estradiol and 47.4%
higher level of free testosterone among women with six or more
nevi compared to those with no nevi, both p for trend=0.001;
Table 3). Both of these associations remained significant after
adjusting for multiple comparisons (0.05/6=0.008 for each of the
six hormonal markers). The correlations between nevus count and
hormonal levels were moderate (r
2=0.30 for free estradiol and
0.09 for free testosterone).
We further conducted a case-control study among a subgroup of
362 breast cancer cases and 611 controls matched for plasma
hormone levels to adjust for hormone levels in the association
between nevi and breast cancer risk: the multivariable-adjusted
odds ratio for every five nevi was attenuated from 1.25 (95% CI,
0.89–1.74) to 1.16 (95% CI, 0.83–1.64) after adjusting for plasma
hormone levels. The hormones that we adjusted for were estradiol,
testosterone, sex hormone–binding globulin, dehydroepiandros-
terone sulfate, free estradiol, and free testosterone. These data
suggest that the association between nevus count and breast cancer
risk was at least partially mediated through hormone levels.
We further evaluated the association between the number of
cutaneous nevi and breast cancer risk by restricting analysis to the
subgroup of postmenopausal women without PMH use in our
cohort, and detected an unchanged HR from that in the overall
population (multivariable-adjusted HR, 1.08).
We also examined the interactions between the number of
cutaneous nevi and other risk factors for breast cancer, and there
was no significant interaction after adjusting for multiple
comparisons (p for interaction=0.38 for current body mass index,
0.39 for body mass index at age 18 y, 0.87 for height, 0.75 for
physical activity, 0.01 for multivitamin use, 0.80 for smoking
status, 0.97 for alcohol consumption, 0.21 for age at menarche,
0.79 for parity and age at first birth, 0.23 for history of benign
breast disease, 0.85 for family history of breast cancer, 0.59 for
menopausal status, and 0.38 for PMH use). Additionally, the
stratification analysis by menopausal status showed significant
associations between the number of cutaneous nevi and breast
cancers for both pre- and postmenopausal women, with an HR of
1.20 (95% CI, 1.04–1.40) for premenopausal women and an HR
Cutaneous Nevi and Breast Cancer Risk
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interaction=0.59; Table S2).
Previous studies have suggested a possible role of sun exposure/
vitamin D on breast cancer prevention. Thus, we additionally
adjusted for the UV flux, outdoor activity, hair color, and skin
tanning ability in this study: the HR for breast cancer remained
unchanged after the adjustment (multivariable-adjusted HR, 1.08,
95% CI, 1.03–1.13). No interaction was detected between these
factors and nevus count after adjusting for multiple tests (p for
interaction=0.87, 0.89, 0.93, and 0.68 for UV flux at birth, age
15 y, age 30 y, and the current year, respectively; 0.62, 0.30, 0.07,
and 0.04 for outdoor activity during high school and at ages 25–
35, 36–59, and 60–65 y, respectively; 0.39 for hair color; and 0.39
for skin tanning ability).
Discussion
In this large prospective cohort study, we identified a significant
positive association between the number of cutaneous nevi and the
incidence of invasive breast cancer. This association was
independent of the previously known risk factors for breast cancer,
and the risk increased with the number of cutaneous nevi in a
dose–response relationship. We further found that postmenopaus-
al women with more cutaneous nevi had higher levels of plasma
total and free testosterone and estradiol, and that the number of
cutaneous nevi was associated with increased risk of breast cancer
only among ER-positive tumors, suggesting that a hormonal effect
underlies this association.
Melanocytes have been postulated to exhibit some degree of sex
hormone responsiveness [14]. Estrogen and androgen receptors
have been found in melanocytes, and melanogenesis is responsive
to these steroid hormones [15]. Taken together with the
phenomenon that melanocytic nevi commonly darken and/or
enlarge during pregnancy, our present finding that women with
more cutaneous nevi had increased plasma levels of free androgen
and free estrogen further supports the association between
cutaneous nevi and sex hormones.
In addition, high levels of pre-diagnostic circulating estrogens
and androgens are consistently associated with increased risk of
breast cancer, especially among postmenopausal women [16].
Estrogens can bind to ERs and contribute to the growth of breast
cancer, and androgens may act directly, promoting cellular growth
and proliferation via binding to the androgen receptor [17], or
indirectly, via their aromatization to estrogens, either peripherally
or in breast tissue [18]. More recently, a nested case-control study
of breast cancer within the NHS cohort found that higher plasma
free testosterone and free estradiol levels were significantly
associated with increased risk of breast cancer, and the stratifica-
tion analysis by ER/PR status showed significant associations only
among ER+ tumors [10]. Consistent with these findings, we found
increased risk of breast cancer among women with more
cutaneous nevi, and this association held only among ER+ tumors.
Our study has several strengths. First, this is a prospective
cohort study with a large sample size and long follow-up,
providing robust evidence of the association between the number
of cutaneous nevi and breast cancer risk. Second, we updated
assessments of previously identified risk factors for breast cancer
periodically and thoroughly adjusted for these factors. Thus, we
were better able to examine the association of breast cancer with
the number of cutaneous nevi independent of previously known
risk factors for breast cancer. Third, we identified the number of
cutaneous nevi as a phenotypic marker for plasma sex hormone
levels, which suggests a possible mechanism underlying the
association of breast cancer with cutaneous nevi. In addition, a
single plasma hormone measurement provides a reasonable
measure of levels over multiple years and may predict breast
Table 1. Baseline characteristics of women according to the self-reported number of cutaneous nevi.
Characteristic Number of Cutaneous Nevi p-Value
None (n=47,052) 1–5 (n=24,017) 6–14 (n=2,789) 15+ (n=665)
Mean age, y (SD) 52.7 (7.2) 52.0 (7.1) 51.9 (7.1) 52.0 (7.2) ,0.01
Body mass index, kg/m
2 (SD) 25.1 (4.7) 25.6 (4.9) 26.5 (5.5) 26.8 (5.7) ,0.01
Body mass index at age 18 y, kg/m
2 (SD) 21.3 (3.0) 21.4 (3.0) 21.7 (3.2) 22.0 (3.6) ,0.01
Height in 1976, m (SD) 64.4 (3.1) 64.5 (3.2) 64.7 (3.0) 64.8 (2.5) ,0.01
Physical activity, MET h/wk (SD) 14.1 (20.8) 14.0 (20.7) 13.7 (19.5) 14.8 (24.5) 0.56
Multivitamin use, percent 43.0 43.3 42.6 44.3 0.79
Current smoker, percent 22.2 20.4 20.0 19.2 ,0.01
Alcohol consumption, g/d (SD) 6.3 (11.0) 6.1 (10.4) 5.8 (9.8) 5.0 (8.5) ,0.01
Age at menarche #12 y, percent 49.3 48.8 49.6 49.1 0.95
Nulliparous, percent 6.6 6.7 7.5 7.7 0.20
Age at first birth, y (SD) 29.3 (17.2) 29.3 (17.2) 30.2 (18.7) 30.1 (18.3) 0.08
History of benign breast disease, percent 14.9 16.5 16.9 19.8 ,0.01
Family history of breast cancer, percent 10.4 10.8 11.2 9.2 0.52
Postmenopausal, percent 61.0 61.0 60.3 61.2 ,0.01
Duration of menopause among
postmenopausal women, y (SD)
10.2 (6.4) 10.2 (6.7) 10.5 (6.8) 10.7 (6.9) 0.24
Current hormone use among
postmenopausal women, percent
26.7 27.6 28.4 30.8 ,0.01
Based on information collected in the 1986 questionnaire unless specified otherwise.
MET, metabolic equivalent of task; SD, standard deviation.
doi:10.1371/journal.pmed.1001659.t001
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risk conferred by a modifiable risk factor, and while nevi are likely
a marker rather than a risk factor, we calculated the PAR of nevi
to compare them with breast cancer risk factors. We calculated a
PAR of 2.0% for women with 1–5 nevi and 1.2% for women with
six or more nevi. These are on the order of the PARs of modifiable
risk factors for breast cancer reported in previous studies: 2.5%–
5.6% for hormone use, 0%–6.1% for $2 alcoholic drinks daily,
and 4.6%–11.0% for physical inactivity [19].
One limitation of this study is that the number of cutaneous nevi
in our cohort was self-reported. However, the majority of studies
on cutaneous nevi have shown a substantial agreement between
nevus self-counts and dermatologist counts, as well as a high
reproducibility [20]. In addition, we collected information on
nevus count of nevi of $3 mm diameter size on the left arm to
represent the whole body. Examining the upper limbs only was
suggested previously to be a practical and suitable tool for
predicting total nevus count [21]. The self-reported number of
cutaneous nevi in our cohort predicted melanoma risk [22], and
our genome-wide association study on self-reported number of
cutaneous nevi in this cohort confirmed previously identified loci
in nevogenesis [23]. Thus, although the number of cutaneous nevi
was self-reported, these findings suggest it is a valid assessment.
In summary, we identified the number of cutaneous nevi as a
novel phenotypic marker associated with breast cancer risk. Given
that higher numbers of cutaneous nevi reflect higher levels of
plasma free testosterone and free estradiol, the number of
cutaneous nevi may be a surrogate for sex hormone exposure.
Our study was conducted in white individuals, so further studies
are needed to confirm our findings in other populations. In
addition, because our study was observational, these results should
be interpreted cautiously and are insufficient to alter current
clinical recommendations. Nevertheless, our data provide epide-
miological evidence on the possible link between cutaneous nevi
and breast cancer risk and support a need for continued
investigation of this relationship.
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Background. One woman in eight will develop breast
cancer during her lifetime. Breast cancer begins when cells in
the breast acquire genetic changes that allow them to divide
uncontrollably (which leads to the formation of a lump in the
breast) and to move around the body (metastasize). The
treatment of breast cancer, which is diagnosed using
mammography (a breast X-ray) or manual breast examination
and biopsy, usually involves surgery to remove the lump, or
the whole breast (mastectomy) if the cancer has started to
metastasize. After surgery, women often receive chemother-
apy or radiotherapy to kill any remaining cancer cells and may
also be given drugs that block the action of estrogen and
progesterone,female sexhormones thatstimulatethegrowth
of some breast cancer cells. Globally, half a million women die
from breast cancer each year. However, in developed
countries, nearly 90% of women affected by breast cancer
are still alive five years after diagnosis.
Why Was This Study Done? Several sex hormone–related
factors affect breast cancer risk, including at what age a
woman has her first child (pregnancy alters sex hormone
levels) and her age at menopause, when estrogen levels
normally drop. Moreover, postmenopausal women with high
circulating levels of estrogen and testosterone (a male sex
hormone) have an increased breast cancer risk. Interestingly,
moles (nevi)—dark skin blemishes that are a risk factor for
the development of melanoma, a type of skin cancer—often
darken or enlarge during pregnancy. Might the number of
nevi be a marker of hormone levels, and could nevi counts
therefore be used to predict an individual’s risk of breast
cancer? In this prospective cohort study, the researchers look
for an association between number of nevi and breast cancer
risk among participants in the US Nurses’ Health Study (NHS).
A prospective cohort study enrolls a group of people,
determines their baseline characteristics, and follows them
over time to see which characteristics are associated with the
development of certain diseases. The NHS, which enrolled
121,700 female nurses aged 30–55 years in 1976, is studying
risk factors for cancer and other chronic diseases in women.
What Did the Researchers Do and Find? In 1986, nearly
75,000 NHS participants (all of whom were white) reported
how many nevi they had on their left arm. Over the next 24
years, 5,483 invasive breast cancers were diagnosed in these
women. Compared to women with no nevi, women with
increasing numbers of nevi had a higher risk of breast cancer
after adjustment for known breast cancer risk factors.
Specifically, among women with 1–5 nevi, the hazard ratio
(HR) for breast cancer was 1.04, whereas among women with
15 or more nevi the HR was 1.35. An HR compares how often
a particular event occurs in two groups with different
characteristics; an HR greater than one indicates that a
specific characteristic is associated with an increased risk of
the event. Over 24 years of follow-up, the absolute risk of
developing breast cancer was 8.48% in women with no nevi
but 11.4% for women with 15 or more nevi. Notably,
postmenopausal women with six or more nevi had higher
blood levels of estrogen and testosterone than women with
no nevi. Finally, in a subgroup analysis, the association
between number of nevi and breast cancer risk disappeared
after adjustment for hormone levels.
What Do These Findings Mean? These findings support
the hypothesis that the number of nevi reflects sex hormone
levels in women and may predict breast cancer risk. Notably,
they show that the association between breast cancer risk
and nevus number was independent of known risk factors
for breast cancer, and that the risk of breast cancer increased
with the number of nevi in a dose-dependent manner. These
findings also suggest that a hormonal mechanism underlies
the association between nevus number and breast cancer
risk. Because this study involved only white participants,
these findings may not apply to non-white women.
Moreover, the use of self-reported data on nevus numbers
may affect the accuracy of these findings. Finally, because
this study is observational, these findings are insufficient to
support any changes in clinical recommendations for breast
cancer screening or diagnosis. Nevertheless, these data and
those in an independent PLOS Medicine Research Article by
Kvaskoff et al. support the need for further investigation of
the association between nevi and breast cancer risk and of
the mechanisms underlying this relationship.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001659.
N An independent PLOS Medicine Research Article by
Kvaskoff et al. also investigates the relationship between
nevi and breast cancer risk
N The US National Cancer Institute provides comprehensive
information about cancer (in English and Spanish),
including detailed information for patients and profession-
als about breast cancer; it also has a fact sheet on moles
N Cancer Research UK, a not-for profit organization, provides
information about cancer, including detailed information
on breast cancer
N The UK National Health Service Choices website has
information and personal stories about breast cancer; the
not-for profit organization Healthtalkonline also provides
personal stories about dealing with breast cancer
N More information about the Nurses’ Health Study is
available
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